What are the common side effects of fotantinib/fotantinib and how to manage them

Fostamatinib (Fostamatinib), as a selective SYK inhibitor, provides a new therapeutic approach in the treatment of immune thrombocytopenia (ITP). Its unique mechanism makes it powerful in suppressing overactivity of the immune system. However, like all targeted drugs, fotantinib is accompanied by a series of side effects while exerting its therapeutic effect.

One of the most common side effects of fotantinib is hypertension, which may be related to its indirect effect on the renin-angiotensin system. Patients should measure their blood pressure every week during the initial medication and dose adjustment stages and record it in their records. Once an abnormal increase is found, they should consider adjusting the antihypertensive medication or temporarily reducing the dose. In addition, diarrhea is also a common discomfort among patients, usually mild to moderate, but in rare cases it may affect the patient's quality of life. Diarrheal symptoms can be treated symptomatically through dietary adjustments and the use of antidiarrheal drugs such as loperamide. At the same time, water and electrolyte balance should be maintained.

Abnormal liver function is another cause for concern. Fotantinib may cause an increase in ALT, AST and other liver enzymes, especially during long-term treatment. Therefore, it is recommended that patients monitor liver function every month. If there is an increase of more than 3 times of transaminase, it is necessary to consider suspending the medication according to the situation and closely observe the recovery situation. Hematological adverse reactions such as neutropenia or leukopenia have also been reported, which suggests that routine blood tests should be performed regularly during treatment, especially in patients taking combined drugs or with other immunosuppressive backgrounds.

Overall, the adverse reactions of fotantinib are predictable and most controllable. The key lies in early identification, dynamic monitoring and timely intervention. Under the guidance of experienced physicians, the safety of this drug has been confirmed to be within an acceptable range, which is of positive significance for controlling refractory ITP.

Reference materials:https://go.drugbank.com/drugs/DB12010